CellaVision AB Bearer Shs CEVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 227.50
- Day Range
- SEK 223.50–229.50
- 52-Week Range
- SEK 120.00–275.00
- Bid/Ask
- SEK 227.00 / SEK 229.00
- Market Cap
- SEK 5.40 Bil
- Volume/Avg
- 6,302 / 24,481
Key Statistics
- Price/Earnings (Normalized)
- 38.26
- Price/Sales
- 7.63
- Dividend Yield (Trailing)
- 0.99%
- Dividend Yield (Forward)
- 0.99%
- Total Yield
- 0.99%
Company Profile
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 237
- Website
- https://www.cellavision.com
Comparables
Valuation
|
Metric
|
CEVI
|
BICO
|
EPEN
|
|---|---|---|---|
Price/Earnings (Normalized) | 38.26 | — | 16.01 |
Price/Book Value | 7.12 | 0.67 | 2.50 |
Price/Sales | 7.63 | 1.51 | 1.30 |
Price/Cash Flow | 26.40 | — | 7.56 |
Price/Earnings
CEVI
BICO
EPEN
Financial Strength
|
Metric
|
CEVI
|
BICO
|
EPEN
|
|---|---|---|---|
Quick Ratio | 2.21 | 1.76 | 1.03 |
Current Ratio | 3.22 | 2.41 | 1.78 |
Interest Coverage | 47.13 | −16.51 | 7.02 |
Quick Ratio
CEVI
BICO
EPEN
Profitability
|
Metric
|
CEVI
|
BICO
|
EPEN
|
|---|---|---|---|
Return on Assets (Normalized) | 15.38% | −4.22% | 8.07% |
Return on Equity (Normalized) | 20.31% | −6.38% | 19.13% |
Return on Invested Capital (Normalized) | 17.69% | −4.08% | 12.64% |
Return on Assets
CEVI
BICO
EPEN
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mbsxpdnd | Thrybk | $184.2 Bil | |
SYK
| Stryker Corp | Vhdwgdtwg | Wjrsn | $125.1 Bil | |
MDT
| Medtronic PLC | Srtdyspn | Pfwts | $108.5 Bil | |
BSX
| Boston Scientific Corp | Pctzqxrz | Twskvdk | $107.1 Bil | |
EW
| Edwards Lifesciences Corp | Vymlcxpxhv | Qbxcfz | $51.4 Bil | |
DXCM
| DexCom Inc | Fhhsvhpbt | Hrtg | $50.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Zmynvlvsfd | Fkbmm | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Xvvtnqpkj | Lwvltk | $24.4 Bil | |
ALGN
| Align Technology Inc | Dcfszxnsl | Ryznltg | $21.7 Bil | |
PODD
| Insulet Corp | Pcxttgrfc | Lknvlh | $12.2 Bil |